Athersys is a biotechnology company that is focused primarily in the field of regenerative medicine. Co.'s MultiStem® (invimestrocel) cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in late-stage clinical development. By applying its proprietary MultiStem cell therapy product, Co. provides therapeutic product development programs treating neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease and other conditions. Co.'s primary programs are focused in the critical care area, with treatment provided in hospitals often in intensive care situations. We show 52 historical shares outstanding datapoints in our ATHX shares outstanding history coverage, used to compute ATHX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATHX market cap history over the course of time is important for investors
interested in comparing ATHX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATHX versus a peer is one thing; comparing
ATHX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATHX can fluctuate over the course of history.
With this page we aim to empower investors researching ATHX by allowing them to research the ATHX market cap history. |
Free ATHX Email Alerts:
Video: The Importance of Market Cap
